Update from the Phase I/II trial ReGenerate-1 with Remygen[®] []

The main part of the Phase I/II trial ReGenerate-1 with Remygen[®] in type 1 diabetes patients has started and four patients are already included in the trial. Additional patients are scheduled to be included in December and January. Compilation of metabolic results from the completed safety and dose escalation part of the trial awaits a final experimental analysis and is expected to be announced in early 2020.“The recruitment to the main trial is going well and in light of the interesting findings previously shown with GABA in both preclinical and clinical trials, we look forward to being